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Translational research into gut 
microbiota: new horizons on 
obesity treatment: updated 2014
Daniela M. Tsukumo1, Bruno M. Carvalho1, 
Marco A. Carvalho-Filho1, Mário J. A. Saad1
ABSTRACT
Obesity is currently a pandemic of worldwide proportions affecting millions of people. Recent stu dies 
have proposed the hypothesis that mechanisms not directly related to the human genome could be 
involved in the genesis of obesity, due to the fact that, when a population undergoes the same nu-
tritional stress, not all individuals present weight gain related to the diet or become hyperglycemic. 
The human intestine is colonized by millions of bacteria which form the intestinal flora, known as gut 
flora. Studies show that lean and overweight human may present a difference in the composition of 
their intestinal flora; these studies suggest that the intestinal flora could be involved in the develop-
ment of obesity. Several mechanisms explain the correlation between intestinal flora and obesity. The 
intestinal flora would increase the energetic extraction of non-digestible polysaccharides. In addition, 
the lipopolysaccharide from intestinal flora bacteria could trigger a chronic sub-clinical inflammatory 
process, leading to obesity and diabetes. Another mechanism through which the intestinal flora could 
lead to obesity would be through the regulation of genes of the host involved in energy storage and 
expenditure. In the past five years data coming from different sources established causal effects 
between intestinal microbiota and obesity/insulin resistance, and it is clear that this area will open 
new avenues of therapeutic to obesity, insulin resistance and DM2. Arch Endocrinol Metab. 2015;59(2):154-60
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INTRODUCTION
I n recent years, the prevalence of obesity has in-creased rapidly throughout the World (1,2). This 
epidemic is related to the intake of high calorie foods 
associated with sedentary lifestyles (3). The imbalance 
between energy expenditure, caloric intake and energy 
storage, is known to contribute to the development of 
obesity (4). Recent studies have suggested that mecha-
nisms not directly related to the human genome could 
be involved in the genesis of obesity, due to the fact 
that, when a determined population undergoes similar 
nutritional stress, not all individuals become hypergly-
cemic or present diet-related weight gain (5-7).
The human intestine is colonized by millions of bac-
teria, primarily anaerobic bacteria, comprising appro-
ximately 1,000 species (8). The intestinal flora geno-
me has approximately 100 times more genes than the 
human genome (5,9). Normal intestinal flora presents 
different functions that contribute to the functioning 
of our organism, therefore this flora can be considered 
a microbial organ (10,11).
Recently several studies have suggested a direct role 
of the intestinal flora in the development of obesity, as 
the intestinal flora could alter energetic and fat storage 
(4). In this article, we review the potential role of the 
intestinal flora in the development of obesity.
NORMAL GUT MICROBIOTA
A large number of bacteria inhabit the gastrointesti-
nal tract and the genome of these commensal bacteria 
which constitute the intestinal flora is greater than the 
human genome (12,13).  
The stomach and the small intestine are not colo-
nized by a large number of bacteria, as the pancreatic 
secretion and bile acids prevent bacterial proliferation 
(13). The colon however, presents approximately 1012 
microorganisms/g of intestinal content (14) (Figu-
re 1). Recent studies have highlighted that over 90% 
of these bacteria are Bacteroides and Firmicutes (4), 
furthermore, over 90% of these bacteria are compul-
sory anaerobes. The predominant bacterial species are: 
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Figure 1. Relative concentrations of bacteria at various locations within 
the gut. Cfu: colony-forming unit.
Duodenum
101-103 cfu/ml
Stomach
101-103 cfu/ml
Colon
1011-1012 cfu/ml
Jejunum/ileum
104-107 cfu/ml
Bacteroidetes, Eubacterium, Bifidobacterium, Fusobacte-
rium, Peptostreptococcus, amongst others.
infant begins to affect the composition and sequence 
of intestinal colonization. Breast fed newborns present 
differences compared to formula-fed newborns in the 
constitution of their intestinal flora (23). The intestinal 
flora of breastfed newborns limits the over-growth of 
potentially pathogenic bacteria such as Escherichia coli 
and Clostridium perfringens, through the production 
of acetate and lactate (15). The main component of 
the flora of these newborns is Bifidobacterium. Gesta-
tional age also affects the formation of the intestinal 
flora, preterm newborns in the neonatal intensive care 
unit have been observed to have a lower number of 
bacteria species, and the strains tended to be more vi-
rulent (24,25). 
Changes in the composition of intestinal microbiota 
occurs along the human intestinal tract and throughout 
the life of an individual, the composition of the flora 
however is quite stable during most of the individual’s 
life (15). The change to an adult diet, factors of the 
intestinal flora itself, changes in the intestinal environ-
ment, amongst other factors, contribute to the trans-
formation of the intestinal flora into an adult type of 
flora (26,27). 
Age appears to be another factor involved in the mo-
dification of intestinal flora. The elderly present a lower 
number of anaerobic bacteria, and on the other hand, a 
higher number of enterobacteria (28,29). Aging brings 
on a significant increase in the potentially pathogenic 
bacteria such as enterobacterias and Clostridium, and a 
decrease in the Bifidobacterial species, which contribu-
te to the protection of the intestinal tract (30,31).
The intestinal flora may vary considerably from one 
individual to another. As observed in studies with adults 
with a varying degree of kinship, genotype appears to 
be the most important factor in defining the compo-
sition of the flora. Additional factors such as diet, life 
expectancy and age would have a less relevant role in 
the composition of an individual’s flora (28,32).
The intestinal flora plays an essential role in main-
taining normal gastrointestinal tract function; this in-
cludes the digestion of nutrients and immune respon-
se of the gastrointestinal tract. Animal studies using 
germ-free mice revealed that these animals presented 
a decrease in the activity of digestive enzymes, of the 
mucosa-associated lymphoid tissue and reduction of 
motility, muscle wall thickness and vascularization. 
These animals also presented a decrease in serum im-
munoglobulin levels and were more prone to infec-
tions (12,13). 
Commensal bacteria have a fundamental role in 
functioning of the intestine (15). These bacteria are 
known to have several functions, such as cellulose di-
gestion (14) and also form a protective barrier that par-
ticipates in the development of the systemic and mu-
cosal immune system (15). The gut flora is constituted 
by multiple non-pathogenic bacteria, and also contains 
possible pathogenic microorganisms (15).
The composition of the intestinal flora is influen-
ced by several factors and appears to be determined 
during the first year of life (4). Factors that contribute 
to the establishment of the this flora include forms of 
childbirth delivery, diet of the newborn, use of me-
dicine and hygiene level, as the intestine is sterile at 
birth (13,16,17). The establishment of the intestinal 
flora begins at delivery when the newborn comes into 
contact with the bacteria present in the environment, 
in maternal feces and bacteria of the vaginal flora (18). 
The intestinal flora is probably continued to be built 
up for several months after birth, when a stable and 
unique flora is established (19-21). The form of de-
livery may influence the initial intestinal flora compo-
sition. Cesarean section delivered newborns may pre-
sent a 30 day delay in the colonization of the intestine 
with beneficial bacteria such as Bifidobacterium and 
Lactobacillus in comparison to vaginal delivered new-
borns (16,22).
Subsequently, the composition of the intestinal flora 
undergoes substantial modifications and the diet of the 
Gut flora and obesity
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
156 Arch Endocrinol Metab. 2015;59/2
Figure 3. Relative proportion of Firmicutes and Bacteroidetes in lean and 
obese mice.
Figure 2. Schematic view of the possible mechanisms linking gut flora to 
obesity. FIAF: fasting-induced adipose factor; LPL: lipoprotein lipase; LPS: 
lipopolysaccharide.
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GUT MICROBIOTA AND OBESITY
Extraction of additional calories from ingested food
Recent studies have shown that the bacteria present in 
the intestinal flora is capable of altering energy regu-
lation and harvesting energy from nutrients, suggest-
ing that the flora can play a role in the development of 
obesity (4). Moreover, in hyperlipidemic diet-induced 
obesity, the lipopolysaccharide from intestinal bacteria 
could represent a triggering factor for the inflammation 
present in these obesity models (Figure 2).
An animal study using germ-free mice observed 
that these mice, despite ingesting greater amounts of 
food than conventionally raised mice, presented a lo-
wer amount of body fat (8). Subsequently, a study by 
Turnbaugh and cols., highlighted that germ-free mice 
colonized with the gut flora from obese mice, presen-
ted a higher increase in body fat than when they were 
colonized with the flora from lean animals (33). This 
same study showed that obese ob/ob mice (leptin-defi-
cient mice) had a reduced number of Bacteroidetes and 
a proportional increase in Firmicutes, when compared 
to lean mice (ob/+ and +/+) from the same litter. Fur-
thermore, the gut flora of obese mice was observed to 
present an abundance of genes coding for enzymes ca-
pable of digesting polysaccharides from diet not usually 
digestible by human. In addition, these investigators 
proposed the hypothesis that the flora of obese mice 
favored a greater capacity of extracting calories from 
food, as the feces of these mice were observed to have 
less calories and a greater amount of fermentation end-
-products. 
Ley and cols. highlighted the gut flora imbalance 
of ob/ob mice compared to that of lean mice in another 
study, observing a relative increase of 50% of Firmicutes 
and a decrease of 50% of Bacteroidetes in ob/ob mice 
(34) (Figure 3). These same investigators demonstra-
ted that obese individuals presented an intestinal flora 
with a lower proportion of Bacteroidetes than lean per-
sons (35). Weight loss over a one-year period modifies 
the flora of obese individuals, leveling the proportion 
of Firmicutes close to those observed in lean persons.
Other bacteria
Firmicutes
Bacteroidetes
Other bacteria
Bacteroidetes
Firmicutes
ObeseLean
The correlation between intestinal flora and obesi-
ty requires further studies in order to elucidate several 
questions. It is not known yet whether, as proposed by 
studies on transplantation of flora, a significant weight 
gain could occur, over a short period of time, simply 
by a small increase in the extraction of energy (36). A 
diet rich in non-digestible fibers has been observed to 
reduce the severity of diabetes, reduce weight and the 
amount of fat tissue (37,38).
Additionally other important questions remain 
unanswered, for example, in which manner do weight 
differences alter the balance of the intestinal flora is 
not yet clear. Furthermore, the manner by which the 
change in flora could be triggered by the conditions 
of the host organism has not yet been fully elucidated 
(39). The intestinal flora of obese individuals has been 
suggested to undergo changes which would increase 
the extraction of calories from nutrients; this however 
would seemingly be more adaptive if it were to occur in 
individuals who presented weight loss, interestingly ho-
wever it is precisely the intestinal flora of obese human, 
Gut flora and obesity
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who already have high calorie reserves, that has been 
observed to be more efficient (35). 
Induction of subclinical inflammation 
A short time ago, several studies highlighted a correla-
tion between type-2 diabetes and obesity which a state 
of subclinical chronic inflammation in several tissues 
such as the adipose tissue, liver and hypothalamus (40-
44). Based on this observation, a new hypothesis has 
been proposed correlating intestinal flora and obesity 
(Figure 2). The inflammation that leads to diabetes and 
obesity in high-fat diet animal models has been pro-
posed to be triggered by the lipopolysaccharide (LPS) 
of gram-negative bacteria which compose the intestinal 
flora (45). These investigators connected an altered mi-
crobiota composition, brought about by a high-fat diet, 
to an increase in the proportion of gram-negative bacte-
ria compared to gram-positive bacteria, with a decrease 
in Bacteroides, Eubacterium rectal-Clostridium coccoides 
group and bifidobacteria. In this study, the imbalance 
of the intestinal microbiota associated to a high-fat 
diet was correlated to insulin resistance, diabetes, and 
increase in body weight gain and body fat, increase in 
serum LPS and triglycerides levels in the liver. Addition-
ally, another study observed a decrease in hepatic steato-
sis and LPS expression after treating rats with polymixin 
B an antibiotic specific for gram-negative bacteria (46). 
In human, individuals without type 2 diabetes pre-
sented lower levels of serum lipopolysaccaride than pa-
tients with type 2 diabetes, paired by age (47). These 
data corroborate the hypothesis that the development 
of obesity and type 2 diabetes can be correlated to the 
lipopolysaccharide from intestinal flora bacteria. 
Another animal study using ob/ob mice, demons-
trated that the modulation of the gut flora using anti-
biotics (ampicillin and norfloxacin) can reduce hepatic 
steatosis and improve glucose tolerance (48). Moreo-
ver, mice treated with a high-fat diet, were observed 
to present a reduction in intestinal permeability and 
in serum LPS levels, in addition to a decrease in the 
inflammation of adipose tissue and macrophage infil-
tration, after the modification of gut microbiota using 
antibiotics (49-53).
Regulation of genes in the host involved in energy 
storage and expenditure 
In a recent study, Backhed and cols. highlighted that 
control animals compared to germ-free mice, presented 
40% more body fat and approximately 50% more go-
nadal fat (8). After two weeks, germ-free mice who had 
received the gut flora of control mice were observed 
to present an increase of 60% of body fat. Two pro-
teins carbohydrate response element-binding protein 
(ChREBP) and liver sterol response element-binding 
protein type-1 (SREBP-1) were demonstrated to be 
involved in the absorption of monosaccharides in the 
intestine and hepatic lipogenesis induced by the gut 
flora (8).
The authors suggested that the intestinal flora in-
terferes in the energy metabolism through several me-
chanisms, among which is included the absorption of 
short chain fatty acids and monosaccharides, which are 
subsequently transformed into fat in the liver. Further-
more, the intestinal flora would enable the absorption 
of polysaccharides which are not normally digestible 
and enable the regulation of genes in the host which 
are involved in the fat deposit in adipocytes (8). Ba-
ckhed and cols., investigated the role of lacking fas-
ting-induced adipose factor (Fiaf) or angiopoietin-like 
protein 4 in the modulation of microbiota induced-
-weight control and showed that the gut flora suppres-
sed intestinal Fiaf (Figure 2), leading to increased lipo-
protein lipase activity in adipocytes, with a consequent 
increase of fat (8). 
Backhed and cols. (54) suggested that germ-free 
mice were resistant to obesity, even when they consu-
med a diet rich in fat and sugar, through mechanis-
ms that involved an increase in the metabolism of fatty 
acids. They demonstrated an increase in the activity of 
the AMPK (adenosine monophosphate-activated pro-
tein kinase) enzyme, which plays a central role in the 
regulation of homeostasis, as a sensor of the status of 
cell energy in the cell. In addition, an increase in Fiaf le-
vels triggers the production of peroxisome proliferator-
-activated receptor gamma coactivator, increasing the 
expression of genes that regulate the oxidation of fatty 
acids in the mitochondria. In this way, the intestinal flo-
ra appears to influence the energy balance not only by 
enabling the extraction of energy from nutrients, but 
also by influencing the expression of genes with regula-
te energy expenditure and storage (54).
CONCLUSION IN 2009
Studies showing that lean and obese humans present 
differences in intestinal flora, suggest that this flora 
could be involved in the development of obesity. Sever-
Gut flora and obesity
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al mechanisms explain the correlation between intesti-
nal flora and obesity. The intestinal flora would increase 
the energy extraction from non-digestible polysaccha-
rides. Moreover, the lipopolysaccharide from bacteria 
flora would trigger a state of subclinical chronic inflam-
mation, leading to obesity and diabetes. Another mech-
anism through which the intestinal flora would lead to 
obesity would be through the regulation of genes in 
the host, involved in energy storage and expenditure. 
However, further studies are necessary to elucidate sev-
eral issues related to the association between intestinal 
flora and obesity. It is not yet clear whether the change 
in the intestinal flora observed in obese individuals 
causes or is caused by obesity. In addition, it is not yet 
known whether a significant weight gain could occur 
due to a modest increase in calorie extraction. 
The human intestine is colonized by millions of mi-
croorganisms and the modifications in the composition 
of the intestinal flora could constitute a novel type of 
treatment for obesity. Probiotics are live microorganis-
ms that could promote changes in the composition of 
intestinal flora. Prebiotics stimulate the growth and ac-
tivity of commensal bacteria as they are non-digestible 
oligosaccharides fermented by the intestinal flora. An-
tibiotics, probiotics and prebiotics could possibly have 
a role in the manipulation of intestinal flora to treat 
obesity in the future. 
CONCLUSION IN 2014
Since the relationship between obesity and gut mi-
crobiota was established few years ago, the important 
question was whether this relationship is causal. In this 
regard, in the past five years, data coming from differ-
ent sources have shown a causal relationship between 
gut microbiota and obesity (4,5,55), supported by ex-
periments including microbiota modulation and mainly 
transplantation. In addition, studies in mice and in hu-
mans have also shown that gut microbiota have a causal 
role in insulin resistance, which is the primary alteration 
observed in DM2. In this regard, an elegant study of 
Ridaura and cols. (55), demonstrated that microbiota 
transplantation from obese or lean human to germ free 
mice induced obesity or lean phenotypes, respectively. 
They also showed that housing mice with obese mi-
crobiota with mice with lean microbiota prevented the 
development of obese phenotypes in the former (55). 
These data indicated us clearly that microbiota can im-
prove metabolic parameters or even prevent obesity, al-
though the composition of diet will also be important 
(11,14,36,39,55,56). 
In addition to the causal role of intestinal micro-
biota on obesity and insulin resistance, alterations in 
gut microbiota have been reported in association with 
HIV disease progression (57), with olanzapine-induced 
metabolic dysfunction (58) and increasing the risk of 
cardiovascular diseases (59). Gut microbiota can also 
modulate diurnal secretion of glucocorticoids (60), the 
immunity with important role in the regulation of Treg 
cells (61), and surprisingly brain activity (62). These 
alterations/modulations usually are induced by pro-
ducts of bacterial metabolism as short chain fatty acids, 
kinurenin which is a product of tryptophan catabolism 
by some bacteria, choline and phosphatidylcholine which 
will first produce trimethylamine (TMA) and then a 
proatherogenic compound trimethylamine-N-oxide 
(TMAO) and many others not yet identified. 
We should also mention that drugs used in clinical 
practice can have a direct effect on intestinal microbio-
ta, or its metabolism may also be influenced by micro-
biota. Recently it was demonstrated that metformin can 
modulate intestinal microbiota, at least in C. elegans, 
suggesting that the therapeutic effect and also the side 
effects of this drug may also be mediated by microbiota 
(63). Another interesting study in this area is related to 
the inactivation of cardiac drug digoxin by gut bacteria 
(Eggerthella lenta), suggesting an important role of diet 
and microbioma in inducing digitalis intoxication (64).
Finally it is important to recognize that this area su-
ffers an enormous progress in the past years, but the 
ideal microbiota profile to a specific person remains to 
be established. However we should be optimistic be-
cause this new knowledge may allowed us to establish 
new clinical trials with slow release encapsulated micro-
biota or probiotics in order to treat obesity/DM2 or 
even to introduce an important epidemic of leanness. 
Note of Editor: this manuscript is the corrected and revised version, 
and invalidates a previous manuscript published in 2009 that was 
retracted.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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